Half-year results for the six months ended 31 December 2008

Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on developmental disorders, is pleased to announce its half-year results for the six months ended 31 December 2008.

Key points in the year to date

• Detailed review of the NPL-2008 programme underway after headline Phase III SOFIA study results announced on 18 February 2009

• Formulation development, scale up work and demonstration of bio-equivalence with NPL-2008 was completed in H2 2008

• Positive results from Phase IIa study of NPL-2009 in Fragile X Syndrome with publication in a peer-reviewed journal

• Positive results from Phase IIa study of NPL-2005 in Fragile X Syndrome

• Patent filing in connection with NPL-2003 in Obsessive Compulsive Disorder

• Cash, cash equivalents and money market investments of £10.2 million at 31 December 2008 (30 June 2008: £12.7 million)

Neuropharm Group plc’s half-year results for the 6 months ended 31 December 2008 (PDF 65KB)

For further information please contact:

Neuropharm +44 (0) 1372 371 171

Robert Mansfield, Chief Executive Officer

Graham Yeatman, Chief Financial Officer

Piper Jaffray Ltd. +44 (0) 20 3142 8700

Neil Mackison, Rupert Winckler

Buchanan Communications +44 (0) 20 7466 5000

Mark Court, Mary-Jane Johnson, Catherine Breen

Notes to Editors:

About Neuropharm

Neuropharm is a speciality pharmaceutical company focused on the development of medicines for the treatment and management of neurodevelopmental disorders. Please visit www.neuropharm.co.uk for further information.